Erratum to: Effect of 12 months treatment with chondroitin sulfate on cartilage volume in knee osteoarthritis patients: a randomized, double-blind, placebo-controlled pilot study using MRI [Clin Rheumatol, 31, 2012 (1347-1357), Doi 10.1007/s10067-012-2022-4];Effect of 12 months treatment with chondroitin sulfate on cartilage volume in knee osteoarthritis patients: A randomized, double-blind, placebo-controlled pilot study using MRI

Clinical Rheumatology

Volumn 31, Issue 9, 2012, Pages 1347-1357

  Railhac, J J ^a   Zaim, M ^b   Saurel, A S ^c   Vial, J ^a   Fournie, B ^a  

^a CHU PURPAN   (France)

^b Centre d'Immunologie Pierre Fabre   (France)

^c IRPF CDPF   (France)

Author keywords

Chondroitin sulfate; Imaging; Knee osteoarthritis; MRI; Pharmacological treatment

Indexed keywords

CHONDROITIN SULFATE; PLACEBO;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; ARTICULAR CARTILAGE; CARTILAGE; CARTILAGE VOLUME; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CORRELATION COEFFICIENT; DEMOGRAPHY; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; JOINT EFFUSION; KAPPA STATISTICS; KNEE LIGAMENT INJURY; KNEE MENISCUS RUPTURE; KNEE OSTEOARTHRITIS; KNEE PAIN; KNEE RADIOGRAPHY; LEQUESNE INDEX; MALE; MOBILIZATION; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOPHYTE; PHASE 4 CLINICAL TRIAL; PILOT STUDY; POPLITEAL CYST; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; REPRODUCIBILITY; SUBCHONDRAL CYST; SUBCHONDRAL EDEMA; SYNOVITIS; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VISUAL ANALOG SCALE; CONTROLLED CLINICAL TRIAL; METABOLISM; METHODOLOGY; MIDDLE AGED; STATISTICAL MODEL; TIME;

AGED; CARTILAGE; CHONDROITIN SULFATES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MODELS, STATISTICAL; OSTEOARTHRITIS, KNEE; OSTEOPHYTE; PILOT PROJECTS; PLACEBOS; REPRODUCIBILITY OF RESULTS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84867880443     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-014-2724-x     Document Type: Erratum

References (54)

1. Smolen JS (2004) Combatting the burden of musculoskeletal conditions. Ann Rheum Dis 63:329
2. Report of a WHO Scientific Group (2003) The burden of musculoskeletal conditions at the start of the new millenium. WHO Technical Report Series, 919; Geneva
3. Dillon CF, Rasch EK, Gu Q et al (2006) Prevalence of knee osteoarthritis in the United States: arthritis data from the third national Health and nutrition examination survey 1991-1994. J Rheumatol 33:2271-2279 (Pubitemid 44749788)
4. Pouchot J, Coste J, Guillemin F (1999) Impact of osteoarthritis on quality of life. In: Reginster JY, Pelletier JP, Martel-Pelletier J, Henrotin Y (eds) Osteoarthritis clinical and experimental aspects. Heidelberg, Berlin, pp 331-355
5. Altman RD, Hochberg MC, Moskowitz RW et al (2000) Recommendations for the medical management of osteoarthritis of the hip and knee. 2000 Update. Arthritis Rheum 43:1905-1915
6. Jordan KM, Arden NK, Doherty M et al (2003) EULAR recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 62:1145-1155 (Pubitemid 37500619)
7. Zhang W, Moskowitz RW, Nuki G et al (2008) OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthr Cartil 16:137-162 (Pubitemid 351222155)
8. Zhang W, Nuki G, Moskowitz RW et al (2010) OARSI recommendations for the management of hip and knee osteoarthritis Part III: changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthr Cartil 18:476-499
9. Bali JP, Cousse H, Neuzil E (2001) Biochemical basis of the pharmacologic action of chondroitin sulfates on the osteoarticular system. Semin Arthritis Rheum 31:58-68 (Pubitemid 32756172)
10. Malavaki CJ, Asimakopoulou AP, Lamari FN et al (2008) Capillary electrophoresis for the quality control of chondroitin sulfates in raw materials and formulations. Anal Biochem 374:213-220
11. Morreale P, Manopulo R, Galati M et al (1996) Comparison of the antiinflammatory efficacy of chondroitin sulfate and diclofenac sodium in patients with knee ostoarthritis. J Rheumatol 23:1385-1391 (Pubitemid 26258762)
12. Bourgeois P, Chales G, Dehais J et al (1998) Efficacy and tolerability of chondroitin sulfate 1200 mg/day vs chondroitin sulfate 3×400 mg/day vs placebo. Osteoarthr Cartil 6(Suppl A):25-30 (Pubitemid 28255101)
13. Bucsi L, Poor G (1998) Efficacy and tolerability of oral chondroitin sulfate as a symptomatic slow-acting drug for osteoarthritis (SySADOA) in the treatment of knee osteoarthritis. Osteoarthr Cartil 6(Suppl A):31-36 (Pubitemid 28255102)
14. Uebelhart D, Thonar EJM, Delmas PD et al (1998) Effects of oral chondroitin sulfate on the progression of knee osteoarthritis: a pilot study. Osteoarthr Cartil 6(Suppl A):39-46 (Pubitemid 28255104)
15. Uebelhart D, Malaise M, Marcolongo M et al (2004) Intermittent treatment of knee osteoarthritis with oral chondroitin sulfate: a one-year, randomised, double-blind, multicenter study versus placebo. Osteoarthr Cartil 12:269-276 (Pubitemid 38461289)
16. Michel BA, Stucki G, Frey D et al (2005) Chondroitins 4 and 6 sulfate in osteoarthritis of the knee. A randomized controlled trial. Arthritis Rheum 52(3):779-786 (Pubitemid 40365099)
17. Mazières B, Loyau G, Menkès CJ et al (1992) Le chondroïtine sulfate dans le traitement de la gonarthrose et de la coxarthrose. Rev Rhum 59:466-472
18. Mazières B, Combe B, Van Phan A et al (2001) Chondroitin sulfate in osteoarthritis of the knee: a prospective, double blind, placebo-controlled multicenter clinical study. J Rheumatol 28:173-181 (Pubitemid 32062042)
19. Mazières B, Hucher M, Zaïm M et al (2007) Effect of chondroitin sulfate in symptomatic knee osteoarthritis: a multicentre, randomised, double-blind, placebo-controlled study. Ann Rheum Dis 66:639-645 (Pubitemid 46707133)
20. Clegg D, Reda DJ, Harris CL et al (2006) Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med 354(8):795-808 (Pubitemid 43290918)
21. Kahan A, Uebelhardt D, De Vathaire F et al (2009) Long-term effects of chondroitins 4 and 6 sulfate on knee osteoarthritis: the study on osteoarthritis progression prevention, a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 60:524-533
22. Hathcock JN, Shao A (2007) Risk assessment for glucosamine and chondroitin sulfate. Regul Toxicol Pharmacol 47:78-83 (Pubitemid 44765124)
23. McAlindon TE, La Valley MP, Gulin JP et al (2000) Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis. JAMA 15:1469-1475 (Pubitemid 30151826)
24. Leeb B, Sweitzer H, Montag K et al (2000) A metaanalysis of chondroitin sulfate in the treatment of osteoarthritis. J Rheumatol 24:205-211 (Pubitemid 30058651)
25. Richy F, Bruyere O, Ethgen O et al (2003) Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis. Arch Intern Med 163:1514-1522 (Pubitemid 36835094)
26. Reichenbach S, Sterchi R, Scherer M et al (2007) Meta-analysis: chondroitin for osteoarthritis of the knee or hip. Ann Intern Med 146:580-590 (Pubitemid 351650539)
27. Wandel S, Jüni P, Tendal B, et al. (2010) Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis. BMJ 341: c4675. Published online on 16 September 2010. http://www.bmj.com/content/341/bmj. c4675.long
28. Uebelhart D (2008) Clinical review of chondroitin sulfate in osteoarthritis. Osteoarthr Cartil 16:S19-S21
29. Bana G, Jamard B, Verrouil E et al (2006) Chondroitin sulphate in the management of hip and knee osteoarthritis: an overview. Adv Pharmacol 53:507-522
30. Cicuttini FM, Jones G, Forbes A et al (2004) Rate of cartilage loss at 2 years predicts subsequent total knee arthroplasty: a prospective study. Ann Rheum Dis 63(9):1124-1127
31. Wluka AE, Forbes A, Wang Y et al (2006) Knee cartilage loss in symptomatic knee osteoarthritis over 4.5 years. Arthritis Res Ther 8(4):R90
32. Cohen ZA, McCarthy DM, Kwak SD et al (1999) Knee cartilage topography, thickness, and contact areas from MRI: in-vitro calibration and in-vivo measurements. Osteoarthr Cartil 7:95-109 (Pubitemid 29112963)
33. Burgkart R, Glaser C, Hyhlik-Durr A et al (2001) Magnetic resonance imaging-based assessment of cartilage loss in severe osteoarthritis: accuracy, precision, and diagnostic value. Arthritis Rheum 44:2072-2077 (Pubitemid 33644050)
34. Wluka AE, Stuckey S, Snaddon J et al (2002) The determinants of change in tibial cartilage volume in osteoarthritic knees. Arthritis Rheum 46:2065-2072
35. Cicuttini FM, Wluka AE, Stuckey SL (2001) Tibial and femoral cartilage changes in knee osteoarthritis. Ann Rheum Dis 60:977-980 (Pubitemid 32885675)
36. Raynauld JP, Kauffmann C, Beaudoin G et al (2003) Reliability of a quantification imaging system using magnetic resonance images to measure cartilage thickness and volume in human normal and osteoarthritic knees. Osteoarthr Cartil 11:351-360 (Pubitemid 36621845)
37. Raynauld JP, Pelletier JP, Beaudoin G et al (2002) A two-year study in osteoarthritis patients following the progression of the disease by magnetic resonance imaging using a novel quantification imaging system [abstract]. Arthritis Rheum 46:S150
38. Altman RD (2004) Measurement of structure (disease) modification in osteoarthritis. Osteoarthr Cartil 12(Suppl A):S69-S76 (Pubitemid 38950283)
39. Conaghan P (2006) Is MRI useful in osteoarthritis? Best Pract Res Clin Rheumatol 20(1):57-68 (Pubitemid 43230463)
40. Abadie E, Ethgen D, Avouac B et al (2004) Recommendations for the use of new methods to assess the efficacy of disease-modifying drugs in the treatment of osteoarthritis. Osteoarthr Cartil 12 (4):263-268 (Pubitemid 38461288)
41. European Medicines Agency (EMA). Committee for Medicinal Products for Human use (CHMP). Guideline on clinical investigation of medicinal products used in the treatment of osteoarthritis. 20 January 2010. CPMP/EWP/784/97 Rev. 1. http://www.tga.gov.au/pdf/euguide/ewp078497en.pdf. Accessed 21-May-2012
42. Altman R, Asch E, Bloch D et al (1986) Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and therapeutic criteria committee of the American Rheumatism Association. Arthritis Rheum 29:1039-1049
43. Lequesne M, Méry C, Samson M et al (1987) Indexes of severity for osteoarthritis of the hip and knee. Scand J Rheumatol 65(Suppl):85-89 (Pubitemid 17165518)
44. Kellgren JK, Lawrence JS (1957) Radiological assessment of osteoarthritis. Ann Rheum Dis 16:494-501
45. Link TM, Steinbach LS, Ghosh S et al (2003) Osteoarthritis: MR imaging findings in different stages of disease and correlation with clinical findings. Radiology 226(2):373-381 (Pubitemid 36313421)
46. Wildi LM, Raynauld JP, Martel-Pelletier J et al (2011) Chondroitin sulphate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomised, double-blind, placebocontrolled pilot study using MRI. Ann Rheum Dis 70(6):982-989
47. Bruyere O, Reginster JY (2007) Glucosamine and chondroitin sulfate as therapeutic agents for knee and hip osteoarthritis. Drugs Aging 24(7):573-580 (Pubitemid 47195676)
48. Hochberg MC (2010) Structure-modifying effects of chondroitin sulfate in knee osteoarthritis: an updated meta-analysis of randomized placebo-controlled trials of 2-year duration. Osteoarthr Cartil 18 (Suppl 1):S28-S31
49. Martel-Pelletier J, Kwan Tat S et al (2010) Effects of chondroitin sulfate in the pathophysiology of the osteoarthritic joint: a narrative review. Osteoarthr Cartil 18(Suppl 1):S7-S11
50. Black C, Clar C, Henderson R et al (2009) The clinical effectiveness of glucosamine and chondroitin supplements in slowing or arresting progression of osteoarthritis of the knee: a systematic review and economic evaluation. Health Technol Assess 13 (52):1-148
51. Conaghan PG, Felson D, Gold G et al (2006) MRI and noncartilaginous structures in knee osteoarthritis. Osteoarthr Cartil 14(Suppl A):A87-A94
52. Raynauld JP, Martel-Pelletier J, Bias P et al (2009) Protective effects of licofelone, a 5-lipoxygenase and cyclo-oxygenase inhibitor, versus naproxen on cartilage loss in knee osteoarthritis: a first multicentre clinical trial using quantitative MRI. Ann Rheum Dis 68(6):938-947
53. Eckstein F, Cicuttini F, Raynauld JP et al (2006) Magnetic resonance imaging (MRI) of articular cartilage in knee osteoarthritis (OA): morphological assessment. Osteoarthr Cartil 14(Suppl A): A46-A75
54. Raynauld JP, Martel-Pelletier J, Berthiaume MJ et al (2006) Long term evaluation of disease progression through the quantitative magnetic resonance imaging of symptomatic knee osteoarthritis patients: correlation with clinical symptoms and radiographic changes. Arthritis Res Ther 8(1):R21